Boston Advisors LLC decreased its stake in shares of Stryker Corporation (NYSE:SYK) by 2.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 29,801 shares of the medical technology company’s stock after selling 665 shares during the period. Boston Advisors LLC’s holdings in Stryker Corporation were worth $4,136,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of SYK. Bollard Group LLC boosted its position in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock valued at $109,000 after buying an additional 3 shares during the period. Baystate Wealth Management LLC boosted its position in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock valued at $139,000 after buying an additional 22 shares during the period. James Investment Research Inc. bought a new position in shares of Stryker Corporation during the second quarter valued at $155,000. Guardian Life Insurance Co. of America boosted its position in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after buying an additional 9 shares during the period. Finally, Assetmark Inc. boosted its position in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after buying an additional 4 shares during the period. Institutional investors and hedge funds own 73.79% of the company’s stock.
Shares of Stryker Corporation (NYSE SYK) traded down 0.09% during midday trading on Friday, reaching $145.23. The company had a trading volume of 480,663 shares. The stock has a market capitalization of $54.33 billion, a PE ratio of 32.42 and a beta of 0.80. The company’s 50-day moving average is $144.45 and its 200-day moving average is $136.22. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84.
Stryker Corporation (NYSE:SYK) last posted its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.98 billion. During the same quarter in the prior year, the company earned $1.39 earnings per share. Stryker Corporation’s revenue was up 6.1% on a year-over-year basis. On average, equities research analysts forecast that Stryker Corporation will post $6.50 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio is 37.95%.
Several equities analysts have weighed in on the company. Stifel Nicolaus raised their price objective on Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, July 28th. BidaskClub cut Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Goldman Sachs Group, Inc. (The) started coverage on Stryker Corporation in a research note on Tuesday, May 16th. They set a “neutral” rating and a $129.00 price objective on the stock. Cowen and Company set a $150.00 target price on Stryker Corporation and gave the stock an “outperform” rating in a research note on Wednesday, April 26th. Finally, Barclays PLC reiterated a “sell” rating and set a $133.00 target price on shares of Stryker Corporation in a research note on Thursday, April 27th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $144.03.
In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the company’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total value of $2,790,730.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $146.36, for a total value of $731,800.00. Following the completion of the sale, the insider now owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The disclosure for this sale can be found here. In the last three months, insiders sold 32,810 shares of company stock worth $4,754,958. 7.40% of the stock is owned by corporate insiders.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.